Amarin Corporation (AMRN) is based in Dublin, Ireland and its U.S. headquarters is in Bridgewater, New Jersey. Its key product is Vascepa, which is eicosapentaenoic acid, EPA, a component of fish-oil derived omega-3 fatty acids. Vascepa was recently FDA approved to reduce cardiovascular events risk in patients with elevated triglycerides and elevated cardiovascular risk despite on maximally tolerated statins. Amarin’s stock fell 70% earlier this week after an adverse patent decision by a District Court in Nevada. On April 2, 2020, the company filed an appeal against the decision for Federal Circuit Review.